Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2023 Jun 1;32(6):840–847. doi: 10.1158/1055-9965.EPI-22-1208

Figure 1. Plots of signature profiles in the New England Bladder Cancer Study.

Figure 1.

They include the four major mutational signatures (COSMIC signature 1, APOBEC-mediated signatures 2 and 13, and 5*/ERCC2 signature) and the four mutational signatures for nitro-PAHs (1,6-dinitropyrene (1,6-DNP), 1,8-dinitropyrene (1,8-DNP), 3-nitrobenzoic acid (3-NBA), and 6-nitrochysene). The x-axis denotes the 5’ and 3’ nucleotides for each substitution type (e.g., A[T>C]C, thymine to cytosine substitution with 5’ adenine and 3’ cytosine).